• Shareholders approve all items on the agenda
  • Management Board reports in detail on ongoing development projects
  • Supervisory Board and Management Board ratified by a large majority

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual General Meeting on September 27, 2021 - for the protection of all persons involved - in virtual form.

The shareholders were able to follow the virtual Annual General Meeting live in picture and sound via the Company's AGM portal. They followed the proposals of the Management Board and Supervisory Board and approved all the resolutions proposed by the management with large majorities. Both the members of the Management Board and the Supervisory Board were given a vote of confidence with majorities of more than 98 percent each. In its presentation, the Management Board informed the shareholders in detail about the current biosimilar projects as well as about the development of the COVID-19 drug and answered all the questions received in advance.

Voting rights could be executed before and during the virtual Annual General Meeting by postal vote or by authorizing the Company's proxies. A total of around 6.1 million no-par value shares were submitted to the vote, corresponding to 55.36 % of the share capital.

Detailed voting results and further information on the 2021 virtual Annual General Meeting can be found at https://www.formycon.com/en/investor-relations/annual-general-meeting/.